Literature DB >> 12781427

Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.

Victoria Villena1, Angel López-Encuentra, José Echave-Sustaeta, Pedro Martín-Escribano, Blanca Ortuño-de-Solo, Juana Estenoz-Alfaro.   

Abstract

Several tumor markers have been evaluated in pleural fluid, but their clinical role has not been firmly established. The aim of this study is to determine the diagnostic value of carbohydrate antigen 549 (CA 549) levels in pleural fluid, and to compare it with another previously studied tumor markers: carcinoembryonic antigen (CEA), CA 15.3 and CA 72.4. We prospectively studied 252 patients with pleural effusion: 101 malignant (20 mesothelioma) and 151 of several benign diseases. The levels of the tumor markers were measured by immunoradiometric assays (RIA). CA 549 in pleural fluid has an acceptable sensitivity (0.49), with high specificity (0.99). The best combination of tumor markers for differentiating malignant from benign effusions was CA 549+CEA+CA 15.3, with a sensitivity of 0.65, specificity of 0.99 and accuracy of 0.85. The addition of any one tumor marker assay consistently improved the diagnostic value of cytology. In our study, none of the tumor markers was organ-specific. When mesothelioma and hematological malignancy were ruled-out, the combination of CA 549+CEA+CA 15.3, improved the results up to a sensitivity of 0.77, specificity of 1 and accuracy of 0.92. In conclusion, CA 549 assay has an acceptable sensitivity with high specificity. The best combination of tumor markers in this series with a high relative frequency of mesothelioma and low frequency of breast carcinoma was CA 549+CEA+CA 15.3. Individual tumor markers or their combination increased the sensitivity of pleural cytology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781427     DOI: 10.1016/s0169-5002(03)00120-x

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

1.  Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Authors:  Jenette Creaney; Deborah Yeoman; Leanne K Naumoff; Michelle Hof; Amanda Segal; Arthur William Musk; Nicholas De Klerk; Nora Horick; Steven J Skates; Bruce W S Robinson
Journal:  Thorax       Date:  2007-03-13       Impact factor: 9.139

2.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

3.  Diagnostic and predictive role of cell-free midkine in malignant pleural effusions.

Authors:  Mingming Lv; Yongbin Mou; Ping Wang; Yueqiu Chen; Tingting Wang; Yayi Hou
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-05       Impact factor: 4.553

Review 4.  Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.

Authors:  Ping Gu; Gang Huang; Yumei Chen; Cuiying Zhu; Jimin Yuan; Shile Sheng
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

5.  Proteomic study of benign and malignant pleural effusion.

Authors:  Hongqing Li; Zhonghao Tang; Huili Zhu; Haiyan Ge; Shilei Cui; Weiping Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-05       Impact factor: 4.553

Review 6.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.

Authors:  Xin Fan; Yanqing Liu; Zhigang Liang; Shanshan Wang; Jing Yang; Aihua Wu
Journal:  Pathol Oncol Res       Date:  2022-04-20       Impact factor: 2.874

8.  Calprotectin: a novel biomarker for the diagnosis of pleural effusion.

Authors:  N Sánchez-Otero; S Blanco-Prieto; M Páez de la Cadena; L Vázquez-Iglesias; A Fernández-Villar; M I Botana-Rial; F J Rodríguez-Berrocal
Journal:  Br J Cancer       Date:  2012-10-23       Impact factor: 7.640

9.  Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.

Authors:  J Creaney; A Segal; G Sterrett; M A Platten; E Baker; A R Murch; A K Nowak; B W S Robinson; M J Millward
Journal:  Br J Cancer       Date:  2008-04-29       Impact factor: 7.640

10.  Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.

Authors:  ChunHua Xu; LiKe Yu; Ping Zhan; Yu Zhang
Journal:  Eur J Med Res       Date:  2014-05-08       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.